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OBJECTIVE: Obstructive sleep apnea syndrome is characterized by repetitive obstruction of the upper airways, and
it is a risk factor for cardiovascular diseases. There have been several studies demonstrating low levels of nitric oxide
in patients with obstructive sleep apnea syndrome compared with healthy controls. In this study, we hypothesized
that reduced nitric oxide levels would result in high arginase activity. Arginase reacts with L-arginine and produces
urea and L-ornithine, whereas L-arginine is a substrate for nitric oxide synthase, which produces nitric oxide.
METHODS: The study group consisted of 51 obstructive sleep apnea syndrome patients (M/F: 43/8; mean age
49¡10 years of age) and 15 healthy control subjects (M/F: 13/3; mean age 46¡14 years of age). Obstructive sleep
apnea syndrome patients were divided into two subgroups based on the presence or absence of cardiovascular
disease. Nitric oxide levels and arginase activity were measured via an enzyme-linked immunosorbent assay of
serum samples.
RESULTS: Serum nitric oxide levels in the control subjects were higher than in the obstructive sleep apnea patients
with and without cardiovascular diseases (p,0.05). Arginase activity was significantly higher (p,0.01) in
obstructive sleep apnea syndrome patients without cardiovascular diseases compared with the control group.
Obstructive sleep apnea syndrome patients with cardiovascular diseases had higher arginase activity than the
controls (p,0.001) and the obstructive sleep apnea syndrome patients without cardiovascular diseases (p,0.05).
CONCLUSION: Low nitric oxide levels are associated with high arginase activity. The mechanism of nitric oxide
depletion in sleep apnea patients suggests that increased arginase activity might reduce the substrate availability
of nitric oxide synthase and thus could reduce nitric oxide levels.
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& INTRODUCTION
Obstructive sleep apnea syndrome (OSA) is characterized
by repeated episodes of upper airway obstruction during
sleep (1). Obstruction of the upper airway can lead to a
decrease in blood oxygenation and fragmentation of the
sleep cycle (2). Intermittent arterial oxygen desaturation is
believed to be a major cause of cardiovascular alterations,
which occur in patients with OSA. Therefore, OSA has been
associated with cardiovascular disorders such as arterial
hypertension, coronary artery disease, and cerebrovascular
diseases, and it is an independent etiologic factor for
cardiovascular morbidity and mortality (1).
Nitric oxide (NO), which is synthesized from L-arginine
via endothelial nitric oxide synthase (NOS), is a mediator
that induces vasodilatation, inhibits platelet aggregation,
and prevents adhesion of platelets to endothelial cells (3).
Studies have indicated that a primary mechanism of NO
action is the inhibition of smooth muscle cell contraction (2).
Thus, long-term complications of OSA, including systemic
and pulmonary hypertension, myocardial infarction, and
stroke, might be influenced by NO dysregulation. Reports
have shown that NO levels in OSA patients are lower than
in healthy controls (4-8). Asymmetrical dimethyl arginine
(ADMA), an endogenous competitive inhibitor of NOS, has
been shown to be higher in the plasma of OSA patients,
indicating the potential importance of NOS inhibition (9).
Arginase, an enzyme of the hepatic urea cycle, produces
L-ornithine and urea from L-arginine (10,11). Two isoforms
of arginase have been cloned: arginase I is mainly expressed
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in hepatic cell cytosol, and arginase II is expressed in the
mitochondria of extrahepatic tissues, such as kidney and
brain cells, monocytes, and macrophages (12,13). It is
important to note that arginase can also be expressed in
the immune system cells of humans and thus can lead to
inflammation (11). It was demonstrated that arginase could
be identified in human atherosclerotic plaques, mainly
colocalized with macrophages around necrotic cores (14).
Inflammatory processes can lead to endothelial dysfunction
and result in cardiovascular diseases (15). Previous studies
have shown that arginine administration could improve
vascular reactivity and serve as an atheroprotective.
Furthermore, NO production from arginine via endothelial
NOS results in vasorelaxation and is generally regarded as
atheroprotective because arginase can inhibit NO synthesis
by competing with NOS for L-arginine, although the affinity
of L-arginine is much greater for NOS than for arginase (10).
It is very important to determine the mechanism of NO
reduction in OSA patients. We hypothesized that low NO
levels in OSA patients would result in high arginase
activity, which is an alternative pathway for L-arginine
metabolism. To test this hypothesis, we determined the
arginase activity and NO levels in patients with OSA. We
also stratified our patient population according to the
presence of cardiovascular disorders and compared these
two subgroups, i.e., OSA patients with a proven cardiovas-
cular disease (OSA CV(+)) and OSA patients without any
cardiovascular disease (OSA CV(-)).
& PATIENTS AND METHODS
Patient population
The study population consisted of 51 (M/F, 43/8) patients
with OSA and 15 control subjects (M/F, 13/3), all of whom
were examined using computerized polysomnography. All
of the sleep studies were performed in the Sleep Disorders
Laboratory of Su¨reyyapas¸a Chest Diseases Hospital in
Istanbul. All of the patients underwent a standard battery
of examinations, including medical history, physical and
cardiological examinations (blood pressure, heart rate,
electrocardiography [ECG]), and laboratory screening tests.
They were asked to complete an Epworth Sleepiness Scale
and a questionnaire regarding sleep symptoms and medical
history. Anthropometric measurements of body weight and
height were obtained with the patient dressed only in
underwear. BMI was calculated as body weight divided by
the square of height. Diagnosis of OSA was established on
the basis of clinical and polysomnographic criteria (16).
All of the patients had complaints of snoring, witnessed
apnea, daytime sleepiness, and frequent night awakenings.
The results of the sleep study were automatically recorded
and were subsequently reviewed to ensure the accuracy of
the data. OSA was diagnosed based on a review of all of the
data.
An Apnea Hypopnea Index (AHI) .5 was diagnosed as
OSA. The control group was recruited from healthy people
who were free of medications and had no cardiovascular
disease or respiratory disorders. All of the OSA patients and
controls were free of diabetes mellitus type 2 and other
known metabolic disorders, respiratory infections, and
other respiratory disorders at the time of polysomnography.
Routine ECG, echocardiography, and history revealed that
10 patients with OSA also had cardiovascular diseases, i.e.,
coronary artery disease (n = 5), myocardial infarction (n = 2),
and hypertensive heart disease (n = 3), with a mean duration
time of 8¡4 years. Therefore, we divided the OSA patients
into two subgroups: patients with cardiovascular diseases
(OSA CV(+)) and without cardiovascular diseases (OSA
CV(-)). The study protocol was approved by the local
research ethics committee, and all of the subjects provided
written informed consent.
Polysomnography
All of the patients underwent full-night PSG (Comet-
Grass Technologies Astro-Med, West Warwick, Rhode
Island, USA). Standard polysomnographic montages were
used as follows: Four-channel electroencephalography
(EEG, C4-A2, C3-A1, O2-A1, O1-A2); left and right electro-
oculography (EOG); submental electromyography (EMG), a
nasal cannula to record nasal pressure and a thermistor to
monitor nasal and oral airflow; left and right anterior tibialis
movement sensors; respiratory effort by thoraco-abdominal
belts; ECG; finger pulse oximetry; a neck microphone for
recording snoring; and a sensor on the thoracic belt to
record the body posture. PSG recordings were continued for
at least 6 hours.
Sleep stage and respiratory event scorings have been
described previously (17,18). Briefly, apnea was defined as
complete cessation of airflow lasting for at least 10 seconds,
whereas hypopnea was defined as a decrease in airflow, if it
was associated with either arousal (defined as the appear-
ance for 3 seconds of an alpha rhythm on EEG channels or
an increase in the submental EMG signal) or oxygen
desaturation of $3%. AHI was calculated by dividing the
total number of apnea and hypopnea events by the total
sleep time. The minimal oxygen saturation was determined
as the lowest saturation value associated with a respiratory
event. The Oxygen Desaturation Index (ODI) was the
number of times per hour of sleep that the blood’s oxygen
level decreased by 3% or more from baseline. The average
numbers of episodes of apnea and hypopnea per hour of
sleep were calculated and expressed as the AHI. In addition
to clinical symptoms, an AHI of .30 was also used as an
inclusion criterion for the patient population, and an AHI of
,5 was used for the nonapneic healthy controls. On the
morning after PSG, blood pressure was measured with a
pneumoelectric micro-processor–controlled instrument and
was recorded. Additionally, fasting blood samples were
obtained in the morning after the sleep study.
Blood sampling
Peripheral venous blood samples were obtained in the
morning after the diagnostic study night. The blood
samples, centrifuged at 4,000 x g for 10 min, and serum
samples were aliquoted and stored at -20 C˚ for analysis.
Additionally, liver function tests, renal function tests, and
thyroid function tests were performed to determine co-
morbid disorders. Circulating total cholesterol, triglycerides
(TG), high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), glucose, and hsCRP
measurements were also obtained by enzymatic methods,
using commercial kits for standard evaluations.
Measurement of nitric oxide levels and arginase
activity
NO rapidly degrades into nitrate and nitrite. Spectrophoto-
metric quantitation of nitrite using Griess reagent is sensitive,
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but it does not measure nitrate. With a commercial kit, the
reduction of nitrate to nitrite was performed using NADH-
dependent enzyme nitrate reductase, followed by spectro-
photometric analysis of total nitrite using Griess reagent
(OxisResearch, Portland, OR, USA).
The serum activity of arginase I was quantified according
to the manufacturer’s instructions and guidelines for using
the enzyme-linked immunosorbent assay (ELISA) kit, based
on the sandwich principle specific for humans (Hycult
Biotech, Uden, the Netherlands).
All of the biochemical parameters were measured in
duplicate, and the mean value was used in the analyses.
Data analysis
Statistical analyses were performed with the GraphPad
InStat for Windows (San Diego, CA, USA) computer program.
Values are expressed as means ¡ SDs. Comparisons of two
groups were performed using Student’s t test; comparisons
of more than two independent groups were undertaken by
analysis of variance (ANOVA) with Tukey’s post hoc test.
Additionally, Spearman’s rank correlation analysis and
multiple linear regression analysis were applied to the data.
Significance was determined as p,0.05.
& RESULTS
The demographic and anthropometric parameters, med-
ications, cardiovascular findings, sleep tests, and biochem-
ical analysis results for the control subjects and OSA
patients are shown in Table 1.
Comparisons showed significantly higher weight and
BMI values in the OSA patients compared with the control
group (p,0.05). AHI, ODI, and hsCRP levels OSAwere
significantly higher in the OSA patients than in the control
subjects (p,0.001 for both), but the two study groups were
similar in terms of serum lipid parameters and fasting
glucose level. NO levels in the OSA patients and control
subjects were 28.1¡24.1 mM and 43.4¡32.1 mM, respec-
tively (p,0.05). Arginase activity was significantly higher
in the OSA group compared with the control group
(54.7¡27.0 ng/ml vs. 24.6¡27.6 ng/ml; p,0.001).
As shown in Figure 1, the NO levels in the OSA CV(-)
patients were lower than in the healthy controls, but the
difference failed to reach statistical significance. However,
the OSA CV(+) patients had significantly lower (p,0.05) NO
levels than the controls (Figure 1). Arginase activity was
significantly increased (p,0.01) in the OSA CV(-) patients
compared with the healthy group. The OSA CV(+) patients
had significantly higher arginase activity than the OSA
CV(-) patients (p,0.05) and the control subjects (p,0.001;
Figure 2).
There were positive correlations between hsCRP and NO
levels (r = 0.311, p= 0.026) and between hsCRP and AHI
(r = 0,415, p= 0,002) in the OSA patients with and without
cardiovascular diseases. hsCRP and arginase activity were
not correlated in the OSA patients (r = -0.104; p= 0.466). As
expected, a negative correlation between arginase activity
and NO levels was determined in the OSA patients (r =
-0.384, p,0.005). A multiple regression analysis between
NO levels, arginase activity, and BMI in all of the OSA
patients yielded significant results (r2 = 0.1579, p= 0.0162).
Whereas arginase activity made a significant contribution,
the p value of which was 0.0092, the NO level did not, with
a p-value of 0.9854. There were no contributions in the
control subjects (p= 0.6590).
& DISCUSSION
In the present study, we demonstrated that OSA patients
had significantly higher arginase activity and lower NO
levels than healthy controls. In addition, these differences
might have been related to the presence of cardiovascular
disorders. Indeed, in further analysis, we divided OSA
patients into two subgroups regarding the presence of
cardiovascular disorders, and we found that CV-positive
OSA patients showed the highest levels of arginase activity,
whereas healthy controls showed the lowest levels of this
enzyme. The mean arginase activity of the CV-negative OSA
patients was higher than that of the healthy controls and
lower than that of the CV-positive group. To our knowl-
edge, this was the first study that measured arginase
activity in OSA patients. Arginase activity in OSA patients
was correlated with the presence of cardiovascular dis-
orders.
There have been several studies regarding increased
arginase activity in humans (19) and in experimental animal
models (20,21). Jung et al. reported that arginase activity
was upregulated during ischemia-reperfusion in mouse
myocardial tissue. Inhibition of arginase by nor-NOHA, an
arginase inhibitor, protected against myocardial infarction
(20). In another study, inhibition of arginase activity in
vascular smooth muscle cells by the same drug resulted in a
significantly decreased rate of cell proliferation (21). In
parallel with these findings, increased arginase activity was
also shown to contribute to vascular endothelial dysfunction
in diabetes (22). Moreover, it was demonstrated that serum
arginase I activity was significantly increased and that
serum arginine levels were depleted in humans after
myocardial infarction (19). These authors demonstrated that
arginase expression and activity were upregulated in
ischemic myocardium and coronary arterioles following
ischemia-reperfusion (19). All of these previous reports
suggested that a limitation in NO bioavailability could lead
to dysregulation of vascular function and could contribute
to the development of cardiac disorders. In the present
study, arginase activity was significantly higher in the OSA
patients with cardiovascular disorders compared with the
OSA patients without cardiovascular disease. This finding
could have some implications. First, OSA might cause an
increase in arginase activity, which in turn reduces NO
levels through a decrease in arginine availability to nitric
oxide synthase. Reduced NO levels constitute a well-known
pathophysiologic mechanism for the development of car-
diac disorders. Second, increased arginase activity could be
a common pathophysiologic mechanism for the develop-
ment of both sleep apnea and heart diseases. However, the
relationship of arginase activity with sleep apnea remains to
be elucidated. Arginase, which metabolizes L-arginine into
urea and ornithine, competes directly with NOS for L-
arginine. Hence, increases in arginase activity could
decrease tissue and cellular arginine levels, reducing
arginine’s availability to eNOS. This process could lead to
decreased NO production and increased production of
superoxide by eNOS (22).
A significant amount of evidence has shown NO
reduction in patients with OSA, which could be reversed
by nasal continuous positive airway pressure (nCPAP)
CLINICS 2014;69(4):247-252 Arginase activity and NO in OSA
Yu¨ksel M et al.
249
Table 1 - Comparison of demographic, anthropometric, polysomnographic, and biochemical parameters between
controls and obstructive sleep apnea syndrome patients.
Control OSA (all) OSA CV(-) OSA CV(+)
n = 15 n = 51 n = 41 n = 10
Demographic
Mean age, year 46¡14 49¡10 48¡10 53¡6
Male/female, n 13/3 43/8 37/4 6/4
Anthropometric
Height, cm 172¡10 171¡9 172¡8 165¡10d
Weight, kg 81.8¡8.2 90.5¡13.2a 91.3¡13.5 87.5¡11.5
BMI, kg/m2 27.7¡3.9 31.0¡5.4a 30.9¡4.9 31.5¡7.1
Medications
Beta blockers 7 7
ACE inhibitors 4 4
Ca+2 channel blockers 2 2
Salicylic acid 2 12 5 7
Fibrates 2 12 4 8
Statins 3 21 11 10
Cardiovascular Findings
Heart rate (beat/min) 79¡4 79¡8 80¡8 78¡7
SBP (mm Hg) 130¡4 131¡5 130¡4 136¡4c,e
DBP (mm Hg) 76¡4 79¡7 78¡7 82¡5
Sleep Test
AHI, n/h 1.5¡1.7 55.1¡17.2b 54.7¡18.6b 52.5¡16.5b
Min O2, % 89.3¡1.6 73.1¡8.6
b 73.6¡7.7b 71.1¡11.8b
Mean O2, % 92.2¡0.9 90.3¡4.0 90.2¡4.3 90.6¡3.5
ODI, n/h 6.3¡2.3 55.8¡18.5b 56.3¡18.7b 54.1¡18.8b
Biochemistry
Glucose, mg/dl 94.7¡4.7 109.6¡38.6 107.3¡33.3 119.1¡56.7
Triglyceride, mg/dl 210.4¡42.2 214.2¡40.6 211.5¡44.9 211.6¡42.8
Total C, mg/dl 203.7¡138.0 197.6¡121.2 198.8¡104.9 187.5¡154.1
HDL-C, mg/dl 44.9¡13.5 41.0¡7.4 41.2¡7.7 39.8¡5.7
LDL-C, mg/dl 118.1¡35.2 131.5¡33.1 130.9¡32.2 133.7¡36.6
VLDL-C, mg/dl 42.1¡27.6 37.9¡20.9 39.8¡20.9 37.4¡31.0
hsCRP, mg/dl 1.0¡0.7 5.9¡3.9b 6.0¡3.6b 6.2¡3.9b
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AHI, apnea-hypopnea index; Min O2, minimum oxygen level; Mean O2,
mean oxygen level; ODI, oxygen desaturation index; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; VLDL-C, very
low-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; OSA, obstructive sleep apnea syndrome.
Comparison between the control and OSA patient (all) groups was performed using Student’s t test; all of the other comparisons were performed using
Tukey’s post hoc test.
ap,0.05 compared with the control group.
bp,0.001 compared with the control group.
cp,0.01 compared with the control group.
dp,0.05 compared with the OSA CV(-) group.
ep,0.01 compared with the OSA CV(-) group.
Figure 1 - Comparison of nitric oxide levels in control subjects
and in obstructive sleep apnea patients without (obstructive
sleep apnea syndrome cardiovascular (-)) and with cardiovascular
diseases [obstructive sleep apnea syndrome cardiovascular (+))
*p,0.05 compared with the control group.
Figure 2 - Arginase activity in control subjects and in obstructive
sleep apnea patients without (obstructive sleep apnea syndrome
cardiovascular (-)) and with cardiovascular diseases (obstructive
sleep apnea syndrome cardiovascular (+)) **p,0.01 and
***p,0.001 compared with the control group; +p,0.05 com-
pared with the obstructive sleep apnea syndrome cardiovascular
(-) group.
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therapy (6,7,9,23). Plasma or serum NO levels or NO
metabolites are lower in OSA patients (5,24). Some authors
have reported that reduced NO levels were associated with
$20 episodes of AHI (8) or mild/severe OSA (4,7). It was
also concluded that short- and long-term CPAP therapy
could increase NO levels (6,25), reduce oxidative stress, and
improve quality of life (26) in OSA patients. Several
explanatory mechanisms have been suggested for NO
depletion in OSA. First, oxygen is a co-substrate of NOS,
and nocturnal oxyhemoglobin desaturation might result in
depressed NO synthesis (5,9). Second, oxidative stress is
increased in OSA, and the superoxide anion, which is
produced during oxidative phosphorylation, might react
with NO to produce peroxynitrite. NO consumption in this
manner could be responsible for NO depletion (27). Third,
NOS inhibitors could increase in OSA and suppress NO
synthesis. In fact, ADMA, a NOS inhibitor, was shown to
be higher in the plasma samples of OSA patients (28). As a
fourth mechanism for NO depletion in sleep apnea patients,
we suggest the arginase pathway. Increased arginase
activity could reduce the substrate availability of NOS and
thus reduce NO levels.
Inflammation plays a critical role in cardiovascular
disease pathology. It has been reported that hsCRP, an
acute-phase response protein, is higher in OSA patients
(15,29,30). In our study, we demonstrated that hsCRP levels
were higher in OSA patients regardless of the presence of
cardiovascular disease. Ogino et al. showed that arginase I
activity had a significant correlation with hsCRP levels in
healthy humans (13). This correlation was confounded via
RBC or WBC variables. It was concluded that in healthy
humans, the contribution of hepatocyte-derived arginase I
to serum arginase I might be small compared with that to
WBCs and RBCs. In our study, a correlation between hsCRP
levels and arginase activity was not demonstrated in OSA
patients. Several studies have shown that arginase activity is
positively modulated by inflammatory molecules in rat
vascular smooth muscle cells (31,32). In human umbilical
vein endothelial cells, inflammatory molecules upregulated
arginase activity but decreased the cell proliferation rate
(12). In another study of human aortic endothelial cells, CRP
uncoupled with endothelial NOS and decreased the
production of NO (33). With reference to these articles, in
our study, higher hsCRP levels and arginase activity
resulted in lower NO levels in OSA patients. There was a
positive correlation between hsCRP and NO levels and a
negative correlation between NO levels and arginase
activity.
This study had several limitations that deserve comment.
The measurement of arginine levels in plasma samples
would be beneficial because reduced arginine levels might
support our hypothesis. By the same token, decreases in
arginase and arginine lead to the formation of L-ornithine
and urea. Thus, L-ornithine measurements would indicate
arginine consumption via the arginase pathway. Second,
duration of disease could be a significant factor determining
arginase activity levels. Controlling for disease duration
would have increased the validity of our results, but it was
not practically possible to determine the exact time of
disease state because admission time can vary from patient
to patient. Some of the patients might have been admitted to
the sleep laboratory in early stages of the disease and so
were diagnosed early, whereas some other patients might
have been admitted in later stages of the disease and thus
were diagnosed later.
In conclusion, arginase activity was increased in patients
with OSA. Increased arginase activity and reduced NO
levels in OSA patients might be related to the presence
of cardiovascular disorders. Here, we suggest a putative
mechanism regarding NO depletion in OSA, which stresses
increased arginase activity.
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